Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Pharma gets social: new possibilities and handling open dial...

Daniel Ghinn discusses the winners of this year’s Healthcare Engagement Strategy Awards in his latest ‘Pharma gets social’ article. The Healthcare Engagement Strategy Awards, now in their third year, celebrate innovation in healthcare engagement that really makes a...

Articles

Tunnah’s musings: pharma meets biotech - a match made in hea...

In this week’s musings, Paul Tunnah continues his look at the relationship between pharma and biotech, topically asking if they represent the ideal Valentine’s Day partners. Every now and then we all need to let our hair down and it just so happened that the publication date for this piece fell today, February 14th …

Articles

Charting a new course: bold new approaches needed to boost R...

Scott Vogelsberg discusses the current challenges facing R&D and the approaches that need to be taken. Any perusal of pharma-related resources is certain to reveal a flurry of articles and posts centered on a central question...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.